Retatrutide (LY3437943), 99.5% purity peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

Retatrutide (LY3437943) is a synthetic peptide with 99.5% purity that functions as a triple receptor agonist, targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Its molecular structure adopts a single continuous helical conformation, enabling the N-terminal segment to engage the receptor transmembrane domain while the C-terminal segment interacts with extracellular regions of the GLP-1 and GIP receptors. Retatrutide exhibits differential potency, with an EC₅₀ of 0.0643 nM at the human GIP receptor, 0.775 nM at the GLP-1 receptor, and 5.79 nM at the glucagon receptor.

The peptide demonstrates dose-dependent pharmacological activity and has a half-life of approximately six days. It undergoes primarily hepatic metabolism without significant interaction with cytochrome P450 enzymes. Retatrutide's receptor activation leads to measurable changes in metabolic parameters, including reductions in gastric emptying and food intake. These effects contribute to alterations in body weight and glycated hemoglobin levels in experimental models.

• 1. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.
• 2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial [published online ahead of print, 2023 Jun 26]. N Engl J Med. 2023;10.1056/NEJMoa2301972.
• 3. Sanyal, Arun J et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature medicine vol. 30,7 (2024): 2037-2048. doi:10.1038/s41591-024-03018-2
• 4. Ma, Jun et al. “Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.” Endocrine, 10.1007/s12020-024-03998-8. 30 Aug. 2024, doi:10.1007/s12020-024-03998-8
• 5. Ullah MI, Tamanna S. Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies. Medicines (Basel). 2025 Jul 28;12(3):19. doi: 10.3390/medicines12030019. PMID: 40843857; PMCID: PMC12372088.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.